FP7 logo euThe ESNATS project has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F5-2008-201619

Embryonic Stem cell-based Novel Alternative Testing Strategies

Partners: Partners : Avantea (Avantea)

Avantea is a reproductive biotechnology company involved in assisted reproduction, embryonic stem cell culture/differentiation and development of alternative in vitro tests.

In the present project Avantea will develop an in vitro teratogenicity test based on hESC using lines imported from Harvard University. Avantea is involved in ReProTect (LSHB-CT-2004-503257, www.reprotect.eu) on the development on alternative tests in reproductive toxicology and is workpackage leader in the area Fertility that includes embryonic stem cells. Key personnel Giovanna Lazzari and Cesare Galli are inventors in a patent relevant to in vitro toxicity testing.  

Key staff involved in the project

Giovanna Lazzari, project leader, senior research scientists. She is a veterinarian with 18 years of research experience both in public (Babraham Institute, Cambridge UK) and private research organisations. She has a strong cell biology background in particular in stem cell culture, oocyte development embryo and embryonic stem cells culture.

 

 

Cesare Galli, Avantea Director, is part time tenured Professor at the University of Bologna. As expert in stem cell culture, he is coordinator of a European Science Foundation project entitled "novel approaches to enhance animal embryonic stem cell research".

 

Silvia Colleoni, PhD. She is a post-doc with several years of experience in assisted reproduction, cell culture and ES culture/differentiation in particular. She also has a strong molecular biology background and expertise in immunohistochemistry and in vitro toxicology.

 

 

Top ^